2023
Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study
Grinblatt D, Roboz G, Pollyea D, Sekeres M, Scott B, Seiter K, Zeidan A, Patel J, Garcia-Manero G, Komrokji R, Savona M, Degutis I, Kiselev P, Yu E, Heydendael W, Qiu Y, Vergara S, McBride A, Erba H. Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study. Blood 2023, 142: 593. DOI: 10.1182/blood-2023-189963.Peer-Reviewed Original ResearchAcute myeloid leukemiaYears of ageMedian overall survivalProportion of patientsOverall survivalRate of transplantGroup 2Group 1Molecular testingTreatment patternsAML cohortMedian (95% CI) OSMyeloid diseasesReal-world clinical practiceWorld Health Organization criteriaIntensive chemotherapy regimensLow-intensity chemotherapyObservational cohort studyOutcomes of patientsFirst-line treatmentKaplan-Meier methodProspective observational studyYear of diagnosisDate of diagnosisTreatment of patients
2019
Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study
Zeidan A, Gilligan A, Gautam S, Hu N, Grinblatt D, Pandya B. Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study. Blood 2019, 134: 5082. DOI: 10.1182/blood-2019-123535.Peer-Reviewed Original ResearchR AMLHigh-intensity chemotherapyLow-intensity chemotherapyBest supportive careAcute myeloid leukemiaFLT3 mutational statusMajority of ptsElectronic medical recordsFLT3 inhibitorsDifferent anticancer therapiesMutational statusCohort studyInitial diagnosisEMR databaseFMS-like tyrosine kinase 3 (FLT3) mutationsTyrosine kinase 3 mutationsStudy periodSubset of ptsObservational cohort studyRetrospective cohort studyClinical research nursesAnticancer therapyConfirmation of diagnosisImportant therapeutic innovationsInitial AML diagnosis